Basic study on new treatment strategy targeting mevalonate pathway in prostate cancer

• Project/Area Number: 20791102
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Urology
• Research Institution: Gunma University
• Principal Investigator: NOMURA Masashi Gunma University, 大学院・医学系研究科, 助教 (00420167)
• Project Period (FY): 2008 – 2009
• Project Status: Completed (Fiscal Year 2009)
• Budget Amount: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000); Fiscal Year 2009: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2008: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: 前立腺癌 / メバロン酸経路 / スタチン / 脂質 / ゾレドロン酸

Research Abstract

In this study, the therapeutic potential of statin and zoledoronic acid, mevalotate pathway targeting agents, was studied. Both agents inhibited prostate cancer cell proliferations, especially, statins specifically inhibited proliferation of PC-3, androgen-independent cells. Prostate cancer cells expressed LDL receptor. LNCAP cells had abilities to regulate expression of LDL receptor in response to exogeneous or endogenouse lipid levels. In contrast, PC-3 lacked this ability and statin exerts its antiproliferative effect in PC-3 cells. These results suggested that mevalonate targeting agents, such as statin and zoledoronic acid, have potentials to use for prostate cancer.